Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
John F. Seymour(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Cathy E. Nolan(Abbott Fund), Sari H. Enschede(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), David C.S. Huang(Indonesia International Institute for Life Sciences), John M. Pagel(University of Washington), David E. Darden(Abbott Fund), Alison M. Graham(Abbott Fund), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Dana-Farber Cancer Institute), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Jianning Yang(AbbVie (United States)), Thomas P. Miller(Queen Elizabeth University Hospital), Elisa Cerri(AbbVie (United States)), Todd Busman(Abbott Fund), Lori A. Gressick(AbbVie (United States))
Cited by 33
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k